Glura M XR Forte Tablet is a combination oral antidiabetic medication containing Sitagliptin 100 mg and Metformin 1000 mg, formulated to improve glycemic control in adults with type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the levels of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby aiding in the regulation of blood glucose levels. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity. The extended-release formulation of Glura M XR Forte ensures a gradual release of active ingredients, promoting better tolerability and adherence by minimizing gastrointestinal side effects commonly associated with immediate-release metformin. This combination is indicated as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on metformin alone or those already receiving the combination therapy. It is essential to monitor renal function prior to initiation and periodically during treatment due to the risk of lactic acidosis associated with metformin. Glura M XR Forte should be used under medical supervision, with dose adjustments based on therapeutic response and tolerability.